PACLITAXEL | N216338 | TEVA PHARMACEUTICALS INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 1 | Active | Dana-Farber Cancer Institute | 100 | 2018-11-05 → 2030-09-01 | |
| Phase 2 | Active | AstraZeneca | 126 | 2021-12-10 → 2026-11-30 | |
| Phase 2 | Active | Medical College of Wisconsin | 36 | 2020-03-05 → 2030-08-12 | |
| Phase 1 | Active | National Cancer Institute (NCI) | 20 | 2011-02-09 → 2027-04-17 | |
| Phase 2 | Active | Rutgers, The State University of New Jersey | 62 | 2015-02-25 → 2041-07 | |
| Phase 3 | Active | University College, London | 500 | 2012-11-08 → 2026-12 | |
| Phase 3 | Active | UNICANCER | 327 | 2018-01-24 → 2026-12-22 | |
| Phase 2 | Active | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 68 | 2008-05 → 2027-02 | |
| Phase 3 | Active | AstraZeneca | 1,118 | 2015-07-21 → 2026-12-31 | |
| Phase 2 | Active | Fudan University | 30 | 2025-04-15 → 2027-11-01 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
Lowest Price
$584.83
Highest Price
$1003.02
FSS NDCs
1
Big4 NDCs
1
| Description | Price | Type | Vendor | Contract End |
|---|---|---|---|---|
| 00480-3290-01PACLITAXEL PROTEIN-BOUND 100MG/VIL INJ | $584.83 | Big4 | Teva Pharmaceuticals USA, Inc. | 04/30/2026 |
| 00480-3290-01PACLITAXEL PROTEIN-BOUND 100MG/VIL INJ | $1003.02 | FSS | Teva Pharmaceuticals USA, Inc. | 04/30/2026 |
Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.
18 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Nov 24, 2023 | SUPPL -1 | View Letter (PDF) |
| May 12, 2023 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.